Clinical trials: Antidepressant
Depression
Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression
The purpose of this study is to determine the safety and effectiveness of s-adenosyl-l-methionine (SAMe) in treating major depression.
- Trial name
- NCT00101452
- Testing
- S-adenosyl-l-methionine, Escitalopram
- Where
- 2 sites in United States
- Volunteers
- 199 people
- Sponsor
- Maurizio Fava, MD
Major Depressive Disorder
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy
The purpose of this study is to determine whether a reduced dose of aripiprazole is effective in treating patients with major depressive disorder
- Trial name
- NCT00683852
- Testing
- Aripiprazole 5mg, Aripiprazole 2mg
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Massachusetts General Hospital
Depression
Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression
PRECISE-D is a single site, randomized, open label 8-week clinical trial that will enroll 70 participants to evaluate if the level of inflammation in our body can predict how we will respond to antidepressants.
- Trial name
- PRECISE-D (NCT03993457)
- Testing
- Escitalopram, Bupropion
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder With Anxious Distress
A Study of JNJ-61393215 in the Treatment of Depression
The purpose of this study is to evaluate the efficacy of JNJ-61393215 as adjunctive treatment compared to adjunctive placebo, as assessed by the change from baseline to week 6 on a 17-item Hamilton Depression Rating Scale…
- Trial name
- NCT04080752
- Testing
- JNJ-61393215
- Where
- 35 sites in United States, Moldova and 3 more
- Volunteers
- 222 people
- Sponsor
- Janssen Research & Development, LLC
Treatment-resistant Depression
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).
- Trial name
- SUSTAIN-2 (NCT02497287)
- Testing
- Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 109 sites in United States, Argentina and 19 more
- Volunteers
- 802 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder Without Psychotic Features
Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression
This is a 6-week comparison of asenapine versus placebo as an add-on to ongoing antidepressant treatment in patients with major depression who have not had a complete therapeutic response to treatment with the antidepressant…
- Trial name
- NCT01670019
- Testing
- Asenapine 5-20 mg daily
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Duke University
Major Depressive Disorder
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).
- Trial name
- NCT02972632
- Testing
- Vortioxetine
- Where
- 25 sites in United States
- Volunteers
- 123 people
- Sponsor
- Takeda
Major Depression, Multiple Sclerosis
Escitalopram (Lexapro) for Depression MS or ALS
The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.
- Conditions
- Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT00965497
- Testing
- escitalopram
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of South Carolina
Major Depression
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
The purpose of the present trial is to test the efficacy of Ayahuasca in treatment-resistant depression. Ayahuasca is a decoction of two plants, long used by Amazonian Amerindians.
- Trial name
- NCT02914769
- Testing
- Ayahuasca
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
Healthy
SSRI Effects on Semen Parameters in Men
According to the National Institute of Mental Health, depressive disorders afflict over six million U.S. men annually. Most cases of moderate or severe depression are treated with antidepressants, including monoamine oxidase…
- Trial name
- NCT00385762
- Testing
- paroxetine
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Anhedonia, Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
- Trial name
- TERPSIS (NCT05165394)
- Testing
- NBI-1065846
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 93 people
- Sponsor
- Neurocrine Biosciences
Adjunctive Treatment of Major Depressive Disorder
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
To evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have an inadequate response to antidepressant therapy
- Trial name
- NCT03968159
- Testing
- Pimavanserin
- Where
- 85 sites in United States, Finland and 7 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Depressive Disorder, Major
Clinical Study to Test a New Drug to Treat Major Depression
In this randomized, double-blind, multi-centre, placebo controlled, exploratory, adaptive design study, the antidepressant and plasma cytokine lowering effects of the GW856553 will be investigated in adult subjects diagnosed with…
- Trial name
- PKI113009 (NCT00976560)
- Testing
- GW856553
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 128 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression
The purpose of this research study is to find out if a test can predict whether someone with depression will get better with treatment.
- Trial name
- NCT00824044
- Testing
- Cognitive Behavioral Therapy (CBT), Escitalopram
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Massachusetts General Hospital
Bipolar Depression
Levetiracetam in the Management of Bipolar Depression
A 6-week outpatient, double-blind, placebo-controlled, add-on trial to investigate the effects of levetiracetam on depressive symptoms in bipolar depressed patients.
- Trial name
- NCT00566150
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Major Depressive Disorder, Treatment Resistant
Nuedexta in Treatment-Resistant Major Depression
There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the NMDA receptor as a novel treatment approach for TRD.
- Trial name
- NCT01882829
- Testing
- dextromethorphan/quinidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- James Murrough
Xerostomia, Depression
Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity
The aim of our study was to evaluate the clinical efficacy of a topical sialogogue spray containing 1% malic acid on patients affected by xerostomia caused by drugs.
- Conditions
- Xerostomia, Depression, Hypertension
- Trial name
- NCT01652001
- Testing
- Malic Acid
- Where
- Spain
- Volunteers
- 185 people
- Sponsor
- Universidad de Granada
Depression, Dysthymic Disorder
Duloxetine Treatment in Elderly With Dysthymia
Dysthymic disorder (DD) denotes chronic depression with fewer symptoms than major depressive disorder (MDD), and it affects ~ 2-4 % of adults with a similar prevalence in the elderly.
- Trial name
- NCT01852383
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York State Psychiatric Institute
Depression, Palliative Care
Methylphenidate for Depressed Cancer Patients Receiving Palliative Care
The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake…
- Conditions
- Depression, Palliative Care, Cancer, Mental Disorder
- Trial name
- NCT00129467
- Testing
- Methylphenidate, Selective Serotonin Uptake Inhibitor (SSRI)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- US Department of Veterans Affairs
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01180400
- Testing
- TC-5214
- Where
- 66 sites in Czechia, Estonia and 8 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca